
Opinion|Videos|January 8, 2025
Recent Safety and Efficacy Updates from the Investigator Initiated Study of Loncastuximab tesirine + Rituximab for the Treatment of R/R FL
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses updates from from the phase 2 study of loncastuximab + rituximab from ASH 2024.
Episodes in this series

Video content above is prompted by the following:
- Discuss the updated results from the phase 2 study of loncastuximab + rituximab in R/R FL presented at ASH 2024
- What were the key efficacy results, what about the safety profile?



















